newsfilter
← Latest News
GlobeNewswire·

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in